Drug intelligence / Profile preview

albendazole + levamisole

Development stage
Unknown
Lead developer
Ben Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Bentex-L is a fixed-dose combination anthelmintic medication developed by Ben Pharmaceuticals, primarily used for the treatment of intestinal parasitic infections. It combines albendazole, a benzimidazole derivative, with levamisole, an imidazothiazole. Albendazole works by binding to the colchicine-sensitive site of parasite beta-tubulin, inhibiting its polymerization into microtubules and thereby disrupting essential metabolic functions like glucose uptake, leading to the parasite's death. Levamisole serves as a nicotinic acetylcholine receptor agonist, inducing persistent depolarization and spastic paralysis in susceptible nematodes, which facilitates their expulsion from the host's gastrointestinal tract. This dual-action approach provides broad-spectrum efficacy against various helminths, including *Ascaris lumbricoides* (roundworm) and hookworms.

Brand names
Bentex-L
02

Targets

TUBB (Tubulin (alpha and beta subunits))L-AChR (Nematode type L acetylcholine receptor)

Beyond the preview

Go deeper on albendazole + levamisole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on albendazole + levamisole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call